Trial Profile
Phase I/II Study of Oral Lenalidomide and High Dose Melphalan Supported by Autologous Peripheral Blood Stem Cell Infusion for Patients With Multiple Myeloma
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 23 Oct 2019
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary) ; Melphalan
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- 03 Oct 2019 Status changed from active, no longer recruiting to completed.
- 26 Jan 2017 Planned primary completion date changed from 1 Aug 2016 to 1 Dec 2017.
- 12 May 2016 Planned End Date changed from 1 Jun 2017 to 1 Dec 2017.